Business Wire

lowRISC Collaborates with Industry Leaders to Create OpenTitan

5.11.2019 17:00:00 EET | Business Wire | Press release

Share

lowRISC C.I.C., the open source silicon and tools collaborative engineering company, today announced that it has partnered with ETH Zürich, Google, G+D Mobile Security, Nuvoton Technology and Western Digital in support of OpenTitan, an open source hardware root of trust (RoT) reference design and integration guidelines that enable chip producers and platform providers to build transparently implemented, high-quality hardware RoT chips tailored for data center servers and other devices.

Security begins with infrastructure, and OpenTitan will help ensure root of trust in hardware, transparently implemented, at the foundation for a multitude of devices such as server motherboards, network cards, routers and IoT. Adopters of this framework can inspect and contribute to OpenTitan’s register-transfer level (RTL) design, firmware, and documentation, helping to build more transparent, trustworthy hardware RoT chips for everyone.

OpenTitan is stewarded by lowRISC, which provides a neutral home for collaborative engineering to develop and maintain open source silicon designs and tools for the long term. As with open source software, open silicon provides a deep level of transparency and therefore auditability, as well as enabling innovation. Shared open infrastructure technology permits focus on product differentiation, with shared costs and substantially reduced overall risk.

The Ibex RISC-V processor core, which was originally developed by ETH Zürich as zero-riscy and contributed to lowRISC earlier this year, forms a key component for OpenTitan. lowRISC is committed to raising the bar for quality in open silicon via a methodical approach that combines the development and use of best practices and coding standards, with rigorous testing and verification.

Key benefits of OpenTitan for chip manufacturers and platform providers include:

  1. Transparent: Adopters can inspect and contribute to OpenTitan’s design, firmware, and documentation, helping to build more transparent, trustworthy hardware RoT chips that benefit everyone.
  2. High-quality: OpenTitan’s goal is to build and maintain a high-quality and logically secure RTL design, firmware, and documentation. The project is staffed by expert engineers focused on rigorous design validation and technical documentation, all based on key learnings from designing Google’s Titan chips.
  3. Flexible: Adopters can increase their total addressable market and reduce costs by using a single platform-agnostic hardware RoT design that can be integrated in data center servers, peripherals, and any other hardware platforms.

“We believe collaboratively developed open source silicon designs provide the flexible, cost effective base needed for future generations of secure hardware products,” said Alex Bradbury, lowRISC CTO. “The lowRISC not-for-profit structure combined with full stack engineering capabilities in-house, enables us to manage high quality projects like OpenTitan, and we look forward to developing this partnership and new ones in the future.”

“At lowRISC, our mission is to establish a vibrant ecosystem around open silicon designs and to help lower the barrier to producing custom chips,” said Gavin Ferris, lowRISC CIC board member. “Creating an ecosystem of like-minded organizations focused on the goal of improving transparency around chips helps increase trust in the overall security of the infrastructure on which software runs. With OpenTitan, enterprise organizations and consumers alike will benefit from services built on a more secure infrastructure that is anchored in transparently implemented OpenTitan chips.”

“Customers are asked to put faith in proprietary hardware RoT chips for their mission-critical systems without the ability to fully understand, inspect and therefore trust them,” said Dominic Rizzo, OpenTitan Lead at Google and lowRISC’s OpenTitan Project Director. “By creating OpenTitan with the broader hardware and academic community, we can leverage the experience and security principles used to create Google’s own Titan chips to make hardware RoT designs more transparent, inspectable, and accessible to the rest of the industry. Security should never be built on opacity.”

Collaboration is fundamental to open silicon and at the core of everything that lowRISC does, bringing to projects a deep understanding of open source licensing, contributor models and community building, and providing a uniquely positioned engineering capability.

About lowRISC

lowRISC C.I.C. is a not-for-profit company that aims to demonstrate, promote and support the use of open-source hardware - bringing the benefits of open-source to the hardware world. We are producing high-quality, security-focused, open, and flexible IP. Our expertise includes the LLVM Compiler, novel hardware security extensions and RISC-V tools, hardware and processor design.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Andrew Back
lowRISC
press@lowrisc.org

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release

NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release

Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release

IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye